iShares MSCI United Kingdom (FTSE) vs Viatris Inc — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.52 (market cap $3.62B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 5.5× iShares MSCI United Kingdom (FTSE)'s market cap, and Viatris Inc pays a 2.75% dividend while iShares MSCI United Kingdom (FTSE) pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI United Kingdom (FTSE) for 46 Days and Viatris Inc for 57 Days on average.
| EWU | VTRS | |
|---|---|---|
Market Cap | $3.62B | $20.03B |
Volume | 923,896 | 14,109,977 |
Sector | Broad Market / Factor | Health |
52-Week High | $49.39 | $18.27 |
52-Week Low | $41.34 | $9.74 |
Typical Hold Time | 46 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Signals from Pluang's Aura AI — not financial advice
EWU trades at $46.23, up 0.65% today, but technical indicators show a bearish trend with 16 sell signals versus 3 buy signals. The stock faces resistance at $47 and finds support at $45. Recent news highlights UK market volatility driven by rising gilt yields and inflation concerns, though some sectors like housebuilders have rallied on government support programs. Financial ratios remain unavailable in current data.
The outlook is cautious due to macroeconomic pressures from rising interest rates and energy costs. Investment opportunities exist in sector-specific rallies, but risks include prolonged inflation and ECB policy tightening. Stock performance hinges on UK economic stability and sectoral resilience amid global volatility.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.
The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →